<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05159115</url>
  </required_header>
  <id_info>
    <org_study_id>MED 358</org_study_id>
    <nct_id>NCT05159115</nct_id>
  </id_info>
  <brief_title>Sucrase-isomaltase Deficiency as a Cause of Irritable Bowel Syndrome</brief_title>
  <official_title>Sucrase-isomaltase Deficiency as a Cause of Irritable Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lovisenberg Diakonale Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lovisenberg Diakonale Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Irritable bowel syndrome (IBS) is a functional disorder causing troublesome symptoms and&#xD;
      reduced quality of life. It affects 10-20% of the population, hence creates large costs for&#xD;
      society. About 30-40% of all IBS patients do not benefit from current treatment options.&#xD;
      Sucrase-isomaltase (SI) deficiency is an unexplored condition, that may explain symptoms in&#xD;
      IBS patients who experience no effect from today's treatments. Currently, a duodenal biopsy&#xD;
      is the gold standard for the diagnosis of SI deficiency, however the condition is not well&#xD;
      investigated. A 13C-labelled breath test holds promise as a non-invasive alternative, but it&#xD;
      has not previously been validated.&#xD;
&#xD;
      This project will address the knowledge gap related to a possible association between SI&#xD;
      deficiency and IBS by addressing two research questions that have never been answered before.&#xD;
      We aim to:&#xD;
&#xD;
        1. Validate the 13C-labelled breath test as a diagnostic tool by assessing the strength of&#xD;
           the association between the breath test and SI activity measured in duodenal biopsies&#xD;
&#xD;
        2. Use the 13C-labelled breath test in a randomized dietary crossover trial comparing a&#xD;
           starch and sucrose reduced diet (SSRD) with the standard low-FODMAP diet in IBS&#xD;
           patients, to evaluate whether SI activity is associated with dietary changes according&#xD;
           to symptom severity and gut microbiota composition&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The projects includes two studies:&#xD;
&#xD;
      Study 1: Validation of the 13C-labelled breath test to diagnose sucrase-isomaltase deficiency&#xD;
&#xD;
      Background: In order to validate the 13C-sucrose breath test to diagnose SI deficiency, the&#xD;
      test result must be compared to the &quot;gold standard&quot; method for diagnosis; i.e. measurements&#xD;
      of enzyme activity from intestinal biopsies by &quot;The Dahlquist Method&quot;, and a reference&#xD;
      material must be established.&#xD;
&#xD;
      Objective: To compare results from the 13C-labelled breath test to enzyme activity measured&#xD;
      in biopsies collected from the proximal small intestine in a limited patient group referred&#xD;
      for a gastroscopic examination.&#xD;
&#xD;
      Design: A cross-sectional study.&#xD;
&#xD;
      Primary endpoint: SI activity as measured with a breath test and enzyme activity with assay&#xD;
      of biopsy material.&#xD;
&#xD;
      Recruitment and patient characteristics: Patients referred for gastroscopic examination with&#xD;
      duodenal biopsies and with suspected GI disorder, will be included consecutively.&#xD;
&#xD;
      Sample size: We aim to include 40 patients. No studies validating breath test results in our&#xD;
      patient group are available. However, based on preliminary results suggesting that 35% of IBS&#xD;
      patients have SI deficiency,13 we are 95% likely to find between 8 and 21 patients with SI&#xD;
      deficiency when examining 40 patients. Assuming 80% concordance between the two methods to&#xD;
      (correct proportion of successes), we would need 12 positive cases. Thus, if 40 individuals&#xD;
      are included, the study is sufficiently powered (alpha=5% and beta=20%, using McNemar's test&#xD;
      of concordance).&#xD;
&#xD;
      Study 2: Sucrase-isomaltase deficiency as a cause of symptoms in patients with irritable&#xD;
      bowel syndrome&#xD;
&#xD;
      Objectives: To examine the effect of a 4-week SSRD on GI- and extraintestinal symptoms, gut&#xD;
      microbiota composition and fecal fermentation in patients with IBS (with and without SI&#xD;
      deficiency), and compare the SSRD with a 4-week low-FODMAP diet to investigate whether the&#xD;
      patients with a breath test result indicating SI deficiency respond better to the SSRD than&#xD;
      the patients with normal SI activity. Gut microbiota have been suggested to have a central&#xD;
      role in IBS etiology, hence evaluation of gut microbiota composition and fecal fermentation&#xD;
      will be included to increase the knowledge regarding the effects of dietary change on gut&#xD;
      microbiota composition and activity related to SI deficiency.&#xD;
&#xD;
      Design: A randomized, open clinical crossover trial with a dietary intervention in a group of&#xD;
      IBS patients, lasting for 4+4 weeks (SSRD vs. low-FODMAP) with a 1-week wash-out period in&#xD;
      between. Breath tests will be taken at inclusion, but the results will be &quot;blinded&quot;, e.g. not&#xD;
      available for anyone conducting the trial before end of the study. A SSRD will be compared to&#xD;
      the low-FODMAP diet. All participants will be given dietary advice from a registered clinical&#xD;
      dietitian. Briefly, all forms of sucrose-containing foods (e.g. sweets, jam, and cakes)&#xD;
      should be avoided, and foods rich in starch should be reduced on the SSRD.&#xD;
&#xD;
      Primary endpoint: Symptom severity by IBS-Symptom Severity Scale (IBS-SSS).&#xD;
&#xD;
      Secondary endpoints: Gut microbiota composition, fecal fermentation measured by short chain&#xD;
      fatty acids (SCFAs) and assessment of quality of life by the Patient Reported Outcome&#xD;
      Measurement Information System (PROMIS-29).&#xD;
&#xD;
      Recruitment and patient characteristics: IBS patients referred to the outpatient clinic at&#xD;
      the Department of Gastroenterology at Lovisenberg Diaconal Hospital for dietary guidance by a&#xD;
      registered dietitian will be consecutively included.&#xD;
&#xD;
      Sample size: The primary end point is change in IBS symptom severity (IBS-SSS) at the end of&#xD;
      the treatment period relative to baseline, and the proportion of responders to the dietary&#xD;
      intervention is based on the recommended cut-off of a reduction (ie, improvement) in total&#xD;
      IBS-SSS score of 50 points, which is considered to be clinically meaningful improvement. To&#xD;
      plan our sample size, we performed a power calculation based on the ability to detect a&#xD;
      difference between the two diets in reduction of IBS-SSS score of at least 50 points with 80%&#xD;
      power, assuming an SD of 100. The calculation indicated that we would need 64 patients. To&#xD;
      allow for 15-20% drop-out, we aim to include 80 patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 3, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IBS symptom severity</measure>
    <time_frame>4 weeks</time_frame>
    <description>Symptom severity measured by the IBS-Symptom Severity Scale (IBS-SSS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gut microbiota composition</measure>
    <time_frame>4 weeks</time_frame>
    <description>Analysis of fecal samples for evaluation of microbiota composition in fecal samples collected at baseline and after each 4-week diet intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal fermentation measured by short chain fatty acids (SCFAs)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Analysis of SCFAs in fecal samples collected at baseline and after each 4-week diet intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life in IBS</measure>
    <time_frame>4 weeks</time_frame>
    <description>Assessment of quality of life by the Patient Reported Outcome Measurement Information System (PROMIS-29)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <condition>Sucrose Intolerance Due to Sucrase-Isomaltase Deficiency</condition>
  <condition>Carbohydrate; Malabsorption</condition>
  <condition>Sucrase Isomaltase Deficiency</condition>
  <condition>Functional Gastrointestinal Disorders</condition>
  <arm_group>
    <arm_group_label>Low-FODMAP diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with IBS on a 4-week low-FODMAP diet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Starch- and Sucrose Reduced Diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with IBS on a s 4-week Starch- and Sucrose Reduced Diet (SSRD).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low-FODMAP diet</intervention_name>
    <description>4 weeks of a diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs)</description>
    <arm_group_label>Low-FODMAP diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Starch- and Sucrose Reduced Diet (SSRD)</intervention_name>
    <description>4 weeks of a diet low in starch and sucrose</description>
    <arm_group_label>Starch- and Sucrose Reduced Diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Validation of the 13C-labelled breath test to diagnose sucrase-isomaltase deficiency (n=40)&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  BMI 18-30 kg/m2&#xD;
&#xD;
          -  Referred for gastroscopic examination with suspected GI disorder&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        â€¢ Unwilling or not capable of signing the informed consent&#xD;
&#xD;
        Sucrase-isomaltase deficiency as a cause of symptoms in patients with irritable bowel&#xD;
        syndrome (n=80)&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  BMI 18-30 kg/m2&#xD;
&#xD;
          -  IBS diagnosis according to Rome IV criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inflammatory bowel disease, celiac disease or diabetes mellitus&#xD;
&#xD;
          -  Chronic immune diseases affecting the GI-system&#xD;
&#xD;
          -  Unwilling/unable to maintain a stable diet throughout the study period&#xD;
&#xD;
          -  Use of antibiotic treatment for the last 4 weeks&#xD;
&#xD;
          -  Currently on a restrictive diet&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 6, 2021</study_first_submitted>
  <study_first_submitted_qc>December 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 15, 2021</study_first_posted>
  <last_update_submitted>December 6, 2021</last_update_submitted>
  <last_update_submitted_qc>December 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
    <mesh_term>Malabsorption Syndromes</mesh_term>
    <mesh_term>Carbohydrate Metabolism, Inborn Errors</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

